SAGA Diagnostics
Liquid biopsy testing specialists. Ultrasensitive cancer diagnosis and monitoring to 0.001% variant frequency.
Liquid biopsy testing specialists. Ultrasensitive cancer diagnosis and monitoring to 0.001% variant frequency.
SAGA Diagnostics is a biotechnology startup, founded in 2016 and headquartered in the United States. The company specializes in liquid biopsy testing with a focus on ultrasensitive cancer diagnosis and monitoring to 0.001% variant frequency. Their expertise lies in molecular genetic analyses of circulating tumor DNA and tissue biopsies. SAGA Diagnostics recently received a significant boost with a kr106.00M Series A investment on June 29, 2021, with prominent investors including Hadean Partners, Segulah Medical Acceleration, and Sciety. This investment highlights the growing interest and support for innovative solutions in cancer diagnostics and personalized medicine.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series A | kr106.00M | 3 |
|
29 Jun 2021 |
| Venture Round | Unknown | 1 | LU Innovation | 08 Sep 2020 |
| Series A | kr40.00M | 3 |
|
11 Jun 2019 |
| Seed Round | €1.00M | 4 |
|
15 Mar 2018 |
| Grant | €50.00K | 1 | EASME - EU Executive Agency for SMEs | 01 Dec 2017 |
No recent news or press coverage available for SAGA Diagnostics.
We care about your data, and we'd love to use cookies make your experience better.
